ENTtoday
  • Home
  • COVID-19
  • Practice Focus
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Departments
    • Issue Archive
    • TRIO Best Practices
      • Allergy
      • Facial Plastic/Reconstructive
      • Head and Neck
      • Laryngology
      • Otology/Neurotology
      • Pediatric
      • Rhinology
      • Sleep Medicine
    • Career Development
    • Case of the Month
    • Everyday Ethics
    • Health Policy
    • Legal Matters
    • Letter From the Editor
    • Medical Education
    • Online Exclusives
    • Practice Management
    • Resident Focus
    • Rx: Wellness
    • Special Reports
    • Tech Talk
    • Viewpoint
    • What’s Your O.R. Playlist?
  • Literature Reviews
    • Allergy
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Events
    • Featured Events
    • TRIO Meetings
  • Contact Us
    • About Us
    • Editorial Board
    • Triological Society
    • Advertising Staff
    • Subscribe
  • Advertise
    • Place an Ad
    • Classifieds
    • Rate Card
  • Search

A Look at Immunotherapy’s Potential for Head and Neck Cancer Treatment

by Susan Bernstein • November 7, 2018

  • Tweet
  • Email
Print-Friendly Version

In principle, anti-PD-1 and anti-PD-L1 work differently than anti-CTLA-4 blockers due to different ligand-receptor interactions, he said. However, in practice, they show similar efficacy and toxicity. Anti-CTLA-4 promotes T cell priming by antigen-presenting cells in the lymph nodes. Anti-PD-1 or anti-PD-L1 promote the affector functions of T cells in tumors. “T-reg cells play a somewhat tricky role—they are a subset of T cells that suppress the immune response. In humans, the role of anti-CTLA-4 and T-regs are still controversial,” he said.

You Might Also Like

No related posts.

Explore This Issue
November 2018

Anti-PD-L1 is a negative co-stimulator, said Dr. Koh. PD-L1 expression is in response to IFN-γ expressed by T cells. This is an example of adaptive resistance: Tumor cells express PD-L1 to protect them from the T cells’ attack, and anti-PD-1 or anti-PD-L1 therapies rescue the T cells from this adaptive resistance.

Researchers must explore the extrinsic control of PD-L1 expression and the intrinsic control of the PD-L1 pathway, said Dr. Koh. Various carcinogenesis-related pathways also trigger PD-L1 expression, and its expression in tumors does not always guarantee the efficacy of anti-PD-1 or anti-PD-L1 therapies. “We have to know the biomarkers to overcome the resistance to checkpoint blockade. We have to know: What is the issue with PD-L1 as a biomarker?” he said.

In general, checkpoint blockade works better for high-frequency, somatic mutation tumors, said Dr. Koh. Due to diverse mechanisms of innate or adaptive resistance, some patients may not respond well to immunotherapy. Researchers must learn more about the role of IFN-γ on cancer cell growth, and the phenomenon of T-cell exhaustion, he said.

“Despite unprecedented efficacy, many patients fail to respond, or they may acquire resistance to the drugs over time,” said Dr. Koh. “There is an urgent need to identify the mechanisms of resistance to predict outcomes and identify targets for combination therapy.”

Combination with Radiation

Would combining immunotherapy and radiation overcome resistance? Recent research is optimistic, said John B. Sunwoo, MD, Edward C. and Amy H. Sewall Professor of Medicine and director of head and neck cancer research at Stanford University.

Immunotherapy includes initiators (ipilimumab) and amplifiers (pembrolizumab or nivolumab) of the immune response. “What are the effects of radiation on the immune response? Radiation is also an initiator,” he said. A 2017 murine study by researchers at the University of Colorado Denver showed that radiation can make the tumor more sensitive to PD-L1 therapy, leading to enhanced tumor control and improved survival (Oncoimmunology. 2017;6(10):e1356153). Several ongoing trials are exploring combination therapy with checkpoint inhibitors and radiation.

Pages: 1 2 3 4 | Single Page

Filed Under: Features Tagged With: AAO-HNS annual meeting, head and neck cancer, head and neck cancer treatment, immunotherapyIssue: November 2018

You Might Also Like:

The Triological SocietyENTtoday is a publication of The Triological Society.

The Laryngoscope
Ensure you have all the latest research at your fingertips; Subscribe to The Laryngoscope today!

Laryngoscope Investigative Otolaryngology
Open access journal in otolaryngology – head and neck surgery is currently accepting submissions.

Classifieds

View the classified ads »

TRIO Best Practices

View the TRIO Best Practices »

Top Articles for Residents

  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Why More MDs, Medical Residents Are Choosing to Pursue Additional Academic Degrees
  • What Physicians Need to Know about Investing Before Hiring a Financial Advisor
  • Tips to Help You Regain Your Sense of Self
  • Should USMLE Step 1 Change from Numeric Score to Pass/Fail?
  • Popular this Week
  • Most Popular
  • Most Recent
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Some Studies Predict a Shortage of Otolaryngologists. Do the Numbers Support Them?
    • Vertigo in the Elderly: What Does It Mean?
    • Complications for When Physicians Change a Maiden Name
    • Neurogenic Cough Is Often a Diagnosis of Exclusion
    • Vertigo in the Elderly: What Does It Mean?
    • New Developments in the Management of Eustachian Tube Dysfunction
    • Some Laryngopharyngeal Reflux Resists PPI Treatment
    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment
    • Eustachian Tuboplasty: A Potential New Option for Chronic Tube Dysfunction and Patulous Disease
    • Tympanoplasty Tips: Otology Experts Give Advice on the Procedure
    • How Treatment for Obstructive Sleep Apnea (OSA) Is Evolving to Give Patients a Better Night’s Sleep
    • Vestibular Schwannoma Position Relative to Internal Auditory Canal Helps Predict Postoperative Facial Function
    • Vocal Fold Lipoaugmentation Provides Long-Term Voice Improvements for Glottal Insufficiency
    • Upper Lateral Cartilage Mucosal Flap Enables the Successful Closure of Larger Septal Perforations

Polls

Do you think there will be a shortage of otolaryngologists in the next five to 10 years?

View Results

Loading ... Loading ...
  • Polls Archive
  • Home
  • Contact Us
  • Advertise
  • Privacy Policy
  • Terms of Use

Visit: The Triological Society • The Laryngoscope • Laryngoscope Investigative Otolaryngology

Wiley
© 2022 The Triological Society. All Rights Reserved.
ISSN 1559-4939

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.